

1300 Eye Street N.W.
Washington, DC 20005
Telephone: 202 659.0100
Facsimile: 202.659.0105
www.novakdruce.com

Novak Druce &
Quigg LLP

Facsimile

RECEIVED
CENTRAL FAX CENTER
AUG 24 2006

To: USPTO – Mail Stop Amendment From: Todd R. Samelman

Fax: (571) 273-8300 Pages 11

Phone: (571) 272-1000 Date: August 24, 2006

In re Application of: BERNDL et al.

Serial No.: 09/914,795

Attorney Docket No.: 49727

Confirmation No.: 4232

Filing Date: 09/05/2001

Attachments: Reply to the Non-final Office Action of May 24, 2006

CONFIDENTIALITY NOTICE: This facsimile and any attachments contain information from the law firm of Novak Druce & Quigg, LLP, which may be confidential and/or privileged. The information is intended to be for the use of the individual or entity named on this facsimile. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of the contents of this facsimile is prohibited. If you receive this facsimile in error, please notify us by reply facsimile immediately so that we can arrange for the retrieval of the original documents at no cost to you.

AUG 24 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 09/914,795
Applicant : BERNDL et al.
Filed : 05 September 2001
Examiner : GOLLAMUDI

Confirmation No.: 4232
TC/A.U. : 1616
Customer No. : 26474
Docket No. : 49727

A PROCESS FOR PRODUCING SOLID CYCLODEXTRIN-CONTAINING DOSAGE FORMS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Certificate of Transmission

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 571-272-3300 on August 24, 2006.

Slawomir Mosiolek
SLAWOMIR MOSIOLEK

AMENDMENT AND REQUEST FOR RECONSIDERATION

Honorable Sir:

This Amendment and Request for Reconsideration is in response to the Non-final Office Action of 24 May 2006. Please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.

BEST AVAILABLE COPY